The Pharma Bureau and the US Consulate recently conducted a crucial discussion on challenges in Pakistan's pharmaceutical industry. Growing difficulties faced by companies, including the investment outflow from Pakistan and a surge in counterfeit medicines, were highlighted as major concerns with potential humanitarian and medical shortages. Despite previous discussions with the Prime Minister, tangible progress is lacking.

The delegation was urged to swiftly address the issues with specific actions, including the immediate approval of 262 pending hardship cases and the implementation of the 2018 Drug Pricing Policy. The urgency of approving hardship cases and adjusting the Consumer Price Index (CPI) for industry growth was emphasized. The delegation committed to collaboration with the UK consulate for prompt resolution, recognizing the gravity of the situation and the need for urgent action.